



THOMSON MEDICAL GROUP LIMITED

(Incorporated in the Republic of Singapore)
(Company Registration No. 199908381D)

RESPONSES TO SHAREHOLDERS QUERIES IN ADVANCE OF OUR 25TH ANNUAL GENERAL MEETING TO BE CONVENED ON 31 OCTOBER 2025

The Board of Directors of Thomson Medical Group Limited (the “**Company**” or “**TMG**”, together with its subsidiaries, the “**Group**”) wishes to announce the following in response to the queries received from shareholders in advance of our 25th Annual General Meeting to be convened on 31 October 2025.

Q1. Vietnam operations

- (a) Revenue of Far East Medical Vietnam Limited and its subsidiaries (“FEMVN”) increased from \$50mil for the financial year ended 30 June 2024 (“FY2024”) to \$98mil for the financial year ended 30 June 2025 (“FY2025”) while net profit has decreased slightly from \$2.8mil in FY2024 to \$2.7mil in FY2025. The Group recorded an impairment loss on goodwill of \$75mil in FY2025 for the acquisition of FEMVN.**
 - (i) Is the above financial performance of FEMVN acceptable and have the investment objectives of this acquisition been met so far?**
 - (ii) Please explain the reasons for the impairment loss of \$75mil. Is this due to the susceptibility of FEMVN to macro and micro economic conditions in Vietnam and/or country risk of Vietnam?**
- (b) With a re-assessment of FEMVN's near term business outlook, can the current financial performance be sustainable? What further drivers or factors can sustain or grow FEMVN's performance further?**

Response from Company

- (a)** FEMVN continues to be accretive to the Group, contributing positively to both top-line growth and positive operating profit. The increase in revenue in FY2025 compared to FY2024 was driven by the full-year revenue contribution from FEMVN, following the acquisition by the Group in December 2023. The strong revenue demonstrated the underlying demand for quality private healthcare in Vietnam and FV Hospital's strong clinical reputation. Despite this, the net profit is below our expectations mainly due to higher operating costs in FY2025 as well as macroeconomic factors such as impact of tariffs in Vietnam.

The \$75mil goodwill impairment is a prudent recalibration of future cash flow projections following a reassessment of FEMVN's near-term business outlook and prevailing macroeconomic and microeconomic conditions in Vietnam. This is a non-cash accounting adjustment that does not affect day-to-day operations, liquidity or the long-term earnings potential of FEMVN. Our investment thesis remains intact: FV Hospital strengthens TMG's regional presence, diversifies our income streams, and positions us strongly in one of Southeast Asia's most promising healthcare growth markets.

- (b) We remain confident in FEMVN's potential. Vietnam has robust economic fundamentals and strong structural demand drivers, including a young and growing middle class, rising expectations of care quality, and increasing preference for international-standard healthcare. FV Hospital is one of the few providers in the market with a strong track record, scale, brand trust, and clinical expertise to serve the growing demand. With the economy and political environment back on track, we expect to commence the H-Building Project, the expansion wing of FV Hospital, in FY2026. The H-Building Project is a strategic step for FV Hospital, aiming to meet the increasing demand for specialised and high-tech medical services. The new space is anticipated to attract more patients, enhance operational efficiencies, and potentially open up new revenue streams. Our continued investment into FV Hospital's expansion is part of a long-term thesis: that Vietnam will be one of the most important healthcare growth markets in Southeast Asia, and that FV Hospital is well-positioned to serve as a trusted provider of international-standard care.

Q2. TMG has recently announced the mega 26-acre integrated healthcare with luxury residences, hospitality, commercial and lifestyle precincts masterplan in the heart of Johor Bahru's city centre, Johor Bay. How will the project be funded given the current elevated gearing?

Response from Company

The Johor Bay project is envisaged to be executed in a phased manner over a period of time, allowing flexibility in funding. Financing for Johor Bay will be prudently structured through phased capital deployment via diversified funding sources including strategic partnerships, external financing and internally generated cash flows.

By Order of the Board

THOMSON MEDICAL GROUP LIMITED

Dr Heng Jun Li Melvin
Executive Director and Group Chief Executive Officer
29 October 2025